Akari Therapeutics, Plc

AKTX

US00972G2075

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 02:00:00 18/05/2024 am IST			5-day change	1st Jan Change
1.52 ^USD	+2.70%		-7.03%	-51.28%

10/05	European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading; End Week Up Nearly 3%	MT
08/05	European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Wednesday Trading	MT

Melissa Bradford-Klug to Step Down as Chief Operating Officer of Akari Therapeutics, Plc

May 01, 2024

Akari Therapeutics, Plc announced that Melissa Bradford-Klug will step down as company's Chief Operating Officer effective May 1, 2024.

Latest news about Akari Therapeutics, Plc

European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading; End Week Up Nearly 3%	10/05	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Wednesday Trading	08/05	MT
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading	06/05	MT
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Set to Close Week Lower	03/05	MT
European Equities Traded in the US as American Depositary Receipts Rise Modestly Higher in Thursday Trading	02/05	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Lower in Wednesday Trading	01/05	MT
Akari Therapeutics, Plc Announces CEO Changes	01/05	CI
Melissa Bradford-Klug to Step Down as Chief Operating Officer of Akari Therapeutics, Plc	01/05	CI
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Monday Trading	29/04	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	24/04	MT
European Equities Traded in the US as American Depositary Receipts Jump in Tuesday Trading	23/04	MT
European Equities Traded in the US as American Depositary Receipts Rebound in Monday Trading	22/04	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	17/04	MT
European Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading	16/04	MT
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading	15/04	MT
ADRs End Lower, Leju Holdings Ltd. Declines 72%	13/04	DJ
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading	12/04	MT
ADRs End Higher, Lixiang Education Holding Co. Ltd. Climbs 69%	12/04	DJ
European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading	11/04	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	10/04	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading	09/04	MT
European Equities Traded in the US as American Depositary Receipts Open Week Higher in Monday Trading	08/04	MT
European Equities Traded in the US as American Depositary Receipts Higher in Friday Trading, Close Out Week Lower	05/04	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading	03/04	MT
European Equities Traded in the US as American Depositary Receipts Fall in Tuesday Trading	02/04	MT

Akari Therapeutics, Plc is a late-stage biotechnology company. The Company is developing advanced therapies for autoimmune and inflammatory diseases. Its lead asset, investigational nomacopan, is a bispecific recombinant inhibitor of complement C5 activation and leukotriene B4 (LTB4) activity. Its pipeline includes a Phase 3 clinical trial program investigating nomacopan for pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). It is conducting a clinical trial of subcutaneous nomacopan for the treatment of HSCT-TMA in pediatrics. The United States Food and Drug Administration (FDA) has granted Rare Pediatric Disease, Orphan Drug, and Fast Track designations to nomacopan for the treatment of pediatric HSCT-TMA. It is also investigating long-acting PASylated-nomacopan (PAS-nomacopan) for treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (dry AMD) in preclinical studies.

Sector

Biotechnology & Medical Research

Calendar

30/05/2024 - Q1 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
AKARI THERAPEUTICS, PLC	-51.28%	1.17Cr
VERTEX PHARMACEUTICALS INCORPORATED	+9.42%	11TCr
REGENERON PHARMACEUTICALS, INC.	+11.84%	10TCr
BIONTECH SE	-14.15%	2.24TCr
ARGENX SE	-1.05%	2.23TCr
GENMAB A/S	-5.29%	1.91TCr
WUXI APPTEC CO., LTD.	-38.29%	1.8TCr
BEIGENE, LTD.	-4.16%	1.79TCr
NEUROCRINE BIOSCIENCES, INC.	+7.99%	1.43TCr
SAREPTA THERAPEUTICS, INC.	+36.24%	1.25TCr

Bio Therapeutic Drugs

Akari Therapeutics, Plc

Equities

AKTX

US00972G2075

Biotechnology & Medical Research

Melissa Bradford-Klug to Step Down as Chief Operating Officer of Akari Therapeutics, Plc

Latest news about Akari Therapeutics, Plc

Chart Akari Therapeutics, Plc

Company Profile

Income Statement Evolution

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs